Biosion

Assets in clinical
development

5
Innovative therapies in
preclinical or clinical
development

10+
Partnered programs

8

RICH PIPELINE OF
BREAKTHROUGH THERAPEUTICS

Download Overview

Molecule: BSI-045B

Modality / Target:

mAb, TSLP
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-502

Modality / Target:

bsAb, targets undisclosed
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-038

Modality / Target:

mAb, CD40
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-060T

Modality / Target:

mAb, Siglec-15
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-585

Modality / Target:

bsAb, PD1/ILT4
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-04702

Modality / Target:

ADC, TROP2
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-082

Modality / Target:

mAb, SIRPα
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-001

Modality / Target:

mAb, HER2
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-075

Modality / Target:

mAb, PVRIG
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-500

Modality / Target:

bsAb, targets undisclosed
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-729

Modality / Target:

bsAb, targets undisclosed
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-712

Modality / Target:

ADC, LIV-1
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Molecule: BSI-709

Modality / Target:

ADC, CDH6
Severe Asthma

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
COPD

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: ANKEBIO - China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III
Auto-Immune

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: OBI - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: Celldex - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: PYXIS - Ex China

Preclinical

Phase I

Phase II

Phase III
Solid Tumors

Partner: CTTQ - China

Preclinical

Phase I

Phase II

Phase III

Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA

Email: BD@Biosion.com

Tel: 1-302-257-5085

PRIVACY NOTICE

Assets in clinical
development

5
Innovative therapies in
preclinical or clinical
development

10+
Partnered programs

8

Filter by:

All categories
Immunology
Oncology

Download Overview

BSI-045B

Modality / Target：

mAb, TSLP

MORE
Severe Asthma

Preclinical

Phase I

Phase II

Phase III

Partner

CTTQ - China
Atopic Dermatitis

Preclinical

Phase I

Phase II

Phase III

COPD

Preclinical

Phase I

Phase II

Phase III
BSI-502

Modality / Target：

bsAb, targets undisclosed

MORE
Auto-Immune

Preclinical

Phase I

Phase II

Phase III

BSI-038

Modality / Target：

mAb, CD40

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III

Partner

CTTQ - China
BSI-060T

Modality / Target：

mAb, Siglec-15

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III

Partner

PYXIS - Ex China
BSI-585

Modality / Target：

bsAb, PD1/ILT4

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III

Partner

Celldex - Ex China
BSI-04702

Modality / Target：

ADC, TROP2

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III

Partner

OBI - Ex China
BSI-082

Modality / Target：

mAb, SIRPα

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
BSI-001

Modality / Target：

mAb, HER2

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III

Partner

ANKEBIO - China
BSI-075

Modality / Target：

mAb, PVRIG

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
BSI-500

Modality / Target：

bsAb, targets undisclosed

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III

Partner

CTTQ - China
BSI-729

Modality / Target：

bsAb, targets undisclosed

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
BSI-712

Modality / Target：

ADC, LIV-1

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III
BSI-709

Modality / Target：

ADC, CDH6

MORE
Solid Tumors

Preclinical

Phase I

Phase II

Phase III

Biosion USA, Inc. 1 Innovation Way, Suite 300, Newark, Delaware 19711, USA

Email: BD@Biosion.com

Tel: 1-302-257-5085

PRIVACY NOTICE